J Clin Oncol 35 (25): 2875-2884, 2017.[PUBMED Abstract] Sledge GW, Toi M, Neven P, et al.: The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
JAMA Oncol 6 (1): 116-124, 2020.[PUBMED Abstract] Kalinsky K, Bianchini G, Hamilton E, et al.: Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: primary outcome of the phase 3 postMONARCH trial.
[Abstract] J Clin Oncol 42 (Suppl 17): A-LBA1001, 2024.